Navigation Links
Prasco Expands Authorized Generic Product Line with Vancocin® HCl Capsules
Date:4/11/2012

CINCINNATI, April 11, 2012 /PRNewswire/ --  Prasco Laboratories announced today it will market the Authorized Generic version of Vancocin® HCl Capsules (vancomycin hydrochloride capsules, USP) in 125 mg, and 250 mg strengths in the U.S. under the Prasco label pursuant to its distribution and supply agreement with ViroPharma Incorporated (NASDAQ: VPHM).  Prasco intends to launch immediately.

"We are pleased to have established this relationship with ViroPharma," said Prasco Chief Executive Officer, Chris Arington.   "Consumers and pharmacists will have as one of their prescription drug choices an Authorized Generic product that provides the identical product, quality, reliability and experience as the brand."

"Prasco is the industry leader in Authorized Generics and we are pleased to have partnered with them on this project," commented Dan Soland, ViroPharma's Chief Operating Officer.  "Through this partnership, patients suffering from dangerous C. difficile infections will now have access to a generic formulation of Vancocin that is identical to the brand, and proven through decades of use to be a high quality treatment for this potentially deadly disease."

Vancocin® HCl is a registered trademark of ViroPharma Incorporated.

About Vancomycin Hydrochloride Capsules

Vancomycin Hydrochloride Capsules are indicated for the treatment of C. difficile-associated diarrhea (CDAD).  Vancomycin Hydrochloride Capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).  Vancomycin Hydrochloride Capsules are contraindicated in patients who have experienced a hypersensitivity to vancomycin.  Vancomycin Hydrochloride Capsules must be given orally for treatment of staphylococcal enterocolitis and CDAD.  Orally administered Vancomycin Hydrochloride Capsules are not effective for other types of infections.  Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of Vancomycin Hydrochloride Capsules for active CDAD.  Monitoring of serum concentrations may be appropriate in some instances. 

Nephrotoxicity has occurred following oral Vancomycin Hydrochloride Capsules therapy and can occur either during or after completion of therapy. The risk is increased in geriatric patients.  Monitor renal function.  Ototoxicity has occurred in patients receiving Vancomycin Hydrochloride Capsules.  Assessment of auditory function may be appropriate in some instances.  Prescribing Vancomycin Hydrochloride Capsules in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.  In clinical trials, the most common adverse reactions (greater than or equal to 10 percent) were nausea (17 percent), abdominal pain (15 percent), and hypokalemia (13 percent).  Patients over 65 years of age may take longer to respond to therapy compared to patients less than 65 years of age.  Clinicians should be aware of the importance of appropriate duration of Vancomycin Hydrochloride Capsules treatment in patients over 65 years of age and not discontinue or switch to alternative treatment prematurely. 

For Vancomycin Hydrochloride Capsules prescribing information, please visit: http://www.prasco.com/downloads/Product%20PIs/66993-211-19.pdf

About Prasco

Vancomycin Hydrochloride Capsules represent the latest product from Prasco in its Authorized Generics program. Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience.  The Prasco business model encourages competition and benefits consumers through significant cost savings. Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and mail order pharmacies.  Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and warehouse facility including DEA-approved capabilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.

 

 

 

 


'/>"/>
SOURCE Prasco
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco® Launches Authorized Generic of Shires Carbatrol®
2. Prasco Announces New, Expanded Roles for Key Executives
3. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
4. Prasco Named Exclusive U.S. Distributor for Selected Aspen Branded Products
5. Prasco® Launches Authorized Generic with Shionogi Inc.
6. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
7. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
8. Prasco to Market Authorized Generic of ZEGERID®
9. Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
10. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
11. Precision Antibody Expands Antibody Characterization Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... May 5, 2017   Provista , a proven leader ... 200,000 customers, today announced Jim Cunniff as the ... executive and business experience to Provista, including most recently serving ... California . He assumed his new role ... a great fit for Provista," says Jody Hatcher , ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step ... Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free ... will be presented by Captain Rommie Duckworth, LP, a career fire captain as well ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan Pediatric Dentistry and ... its patients on Long Island, New York. , Holistic dentistry puts dental ... one of the biggest trends in dentistry today. , Dentist Dr. Marc ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com ... food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ... process. As a result, labels need to deliver simple, transparent and clear messaging. ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the ... sectors, today announced the winners of its 3rd Annual ELITE Awards. The ELITE ... people in the healthcare industry today. , Out of more than 500 submissions, ...
Breaking Medicine News(10 mins):